Articles published by Cybin Inc.
   
    Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit
    
   October 04, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
    Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder
    
   October 03, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
   
    Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial
    
   September 26, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
    Cybin to Participate in the Cantor Global Healthcare Conference
    
   September 25, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
    Cybin Announces Date of Annual and Special Meeting of Shareholders
    
   September 21, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
    Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder
    
   September 21, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
    Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines
    
   September 05, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
    Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program
    
   August 15, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
    Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
    
   August 02, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
    Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units
    
   August 01, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
   
    Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
    
   July 24, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
   
    Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
    
   July 12, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
    Cybin to Participate in PSYCH Symposium London 2023
    
   June 30, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
   
    Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones
    
   June 05, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   
    Cybin to Present at the Jefferies Healthcare Conference
    
   June 01, 2023
   From Cybin Inc.
   Via Business Wire
    Tickers
      CYBN
    
   
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 

